Skip to main content
Premium Trial:

Request an Annual Quote

Packard Completes Sale of Canberra

NEW YORK, Feb 27 - Packard BioScience said Tuesday it completed the sale of its nuclear products division, Canberra Industries, to Cogema of France.

Cogema bought Canberra for $170 million. Packard of Meriden, Conn.,  has said it would use the proceeds of the sale for debt repayment, research and development, and general purposes.

"The sale of our nuclear instruments division positions us as a company focused on the life sciences research industry, with added capital and reduced debt," Emery Olcott, CEO of Packard BioScience, said in a statement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.